


ASTRAZENECA PLC

Interim Financial Statements

30 September 2005

Registered number : 2723534



ASTRAZENECA PLC


BALANCE SHEET

As at 30 September 2005 and 31 December 2004

	Notes	30 September 2005 \$m	31 December 2004 (Restated) \$m
Fixed assets			
Fixed asset investments	4	7,745	7,745
Current assets			
External debtors - other		48	25
Debtors - amounts owed by subsidiaries		18,576	23,228
		18,624	23,253
Total assets		26,369	30,998
Creditors due within one year			
Short-term borrowings		(10)	(4)
Other creditors		(194)	(116)
Amounts owed to subsidiaries		(1,504)	(2,409)
		(1,708)	(2,529)
Net current assets		16,916	20,724
Total assets less current liabilities		24,661	28,469
Creditors due after more than one year			
Loans		(1,031)	(1,030)
Net assets		23,630	27,439
Capital and reserves			
Called-up share capital	5	399	411
Share premium account	6	627	550
Capital redemption reserve	6	48	36
Other reserves	6	1,841	1,841
Profit and loss account	6	20,715	24,601
Shareholders' funds - equity interests	7	23,630	27,439


The interim financial statements on pages 1 to 5 were approved by the Board of Directors on 26 October 2005 and were signed on its behalf by:

Sir Tom McKillop
Director



Jonathan Symonds
Director





ASTRAZENECA PLC

PROFIT AND LOSS ACCOUNT for the period ended 30 September 2005

	Notes	30 September 2005 \$m	31 December 2004 (Restated) \$m
Turnover		-	-
Operating costs		(7)	(9)
Operating loss		(7)	(9)
Income from shares in subsidiary undertakings		-	5
Loss on ordinary activities before interest		(7)	(4)
Net interest and exchange gains/(losses)	2	(20)	388
Profit/(loss) on ordinary activities before taxation		(27)	384
Taxation		(2)	506
Net profit/(loss) for the year		(29)	890
Dividends to Shareholders	3	(1,676)	(1,408)
Loss retained for the year		(1,705)	(518)

STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES for the period ended 30 September 2005

Apart from the gains and losses reported above, the Company has recorded a gain of \$282m in respect of the tax settlement of an unrealised exchange loss in the year ended 31 December 2004.

ASTRAZENECA PLC

NOTES RELATING TO THE FINANCIAL STATEMENTS

1 Basis of presentation of financial information

The AstraZeneca PLC interim financial statements are presented in accordance with the accounting policies set out in the 2004 annual accounts except that, during the period, the Company adopted the provisions of Financial Reporting Standards No.20 "Share-based Payments", No.21 "Events after the Balance Sheet Date", No.23 "The Effects of Changes in Foreign Exchange Rates", No.24 "Financial Reporting in Hyperinflationary Economies", No.25 "Financial Instruments: Disclosure and Presentation" and No.26 "Financial Instruments: Measurement". The adoption of these FRSs had no effect on the accounting policies, net assets or results of the Company, except for FRS21. Under FRS21, proposed dividends are no longer accrued in the balance sheet – accordingly, the net assets at 31 December 2004 were increased by \$1,061m.

These interim financial statements do not constitute statutory accounts of the Company within the meaning of Section 240 of the Companies Act 1985. Statutory accounts for the year ended 31 December 2004 have been filed with the Registrar of Companies. The auditor's report on those accounts was unqualified and did not contain any statement under Section 237 of the Companies Act 1985.

2 Net interest and exchange gains/(losses)

	30 September 2005 \$m	31 December 2004 \$m
Interest payable and similar charges		
Payable to subsidiary undertakings	(15)	(22)
External interest payable	(30)	(25)
Net exchange gains/(losses)	(20)	37
	(65)	(10)
Interest receivable and similar income		
Receivable from subsidiary undertakings	45	398
Net interest and exchange gains/(losses)	(20)	388

NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

3 Dividends to Shareholders

	30 Sep 2005 cents per 25c Share	31 Dec 2004 cents per 25c Share	30 Sep 2005 \$m	31 Dec 2004 (restated) \$m
2 nd interim/Final	64.5	54.0	1,061	914
1 st interim	38.0	29.5	615	494
	102.5	83.5	1,676	1,408

4 Fixed Asset Investments

	Shares \$m	Loans \$m	Total \$m
Cost			
At beginning of period	6,715	1,030	7,745
Additions	-	-	-
Disposals and other movements	-	-	-
At end of period	6,715	1,030	7,745

5 Called-up share capital

	Authorised 30 Sep 2005 \$m	Allotted, called-up and fully paid	
		30 Sep 2005 \$m	31 December 2004 \$m
Ordinary Shares (\$0.25 each)	399	399	411
Unissued Ordinary Share (\$0.25 each)	201	-	-
Redeemable Preference Shares (£50,000)	-	-	-
	600	399	411

The movements in share capital during the period can be summarised as follows:

	No of shares (million)	\$m
At beginning of period	1,645	411
Issue of shares	2	-
Repurchase of shares	(50)	(12)
At end of period	1,597	399

NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

6 Reserves

	Share Premium Account	Capital Redemption Reserve	Other Reserves	Profit and Loss Account (restated)	Total 30 Sep 2005	Total 31 Dec 2004 (restated)
	\$m	\$m	\$m	\$m	\$m	\$m
At beginning of period	550	36	1,841	24,601	27,028	29,362
Net losses for the period	-	-	-	(29)	(29)	1,172
Dividends	-	-	-	(1,676)	(1,676)	(1,408)
Share repurchase	-	12	-	(2,181)	(2,169)	(2,199)
Share premiums	77	-	-	-	77	101
At end of period	627	48	1,841	20,715	23,231	27,028
Distributable reserves at end of period	-	-	668	2,406	3,074	2,269

At 30 September 2005 \$18,309m (31 December 2004 : \$22,923m) of the profit and loss account reserve was not available for distribution. The majority of this non-distributable amount relates to profit arising on the sale of Astra AB to a subsidiary in 1999, which becomes distributable as the underlying receivable is settled in cash. During 2005 \$4,614m of the profit was realised by repayment. Subsequent to the period end a further \$1,442 m was repaid on 21 October 2005 resulting in additional distributable reserves not included in the figures above. Included in other reserves is a special reserve of \$157m, arising on the redenomination of share capital in 1999.

7 Reconciliation of movements in shareholders' funds

	30 September 2005	31 December 2004 (Restated)
	\$m	\$m
Net gains/(losses) for the financial period	(29)	1,172
Dividends	(1,676)	(1,408)
	(1,705)	(236)
Issues of AstraZeneca Ordinary Shares	77	102
Repurchase of AstraZeneca Ordinary Shares	(2,181)	(2,212)
Net reduction to shareholders' funds	(3,809)	(2,346)
Shareholders' funds at beginning of period	27,439	29,785
Shareholders' funds at end of period	23,630	27,439